文献速递造血干细胞移植与细胞治疗

ATG与PTCy在非清髓预处理匹配无关供者造血干细胞移植中的比较

ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning.
PubMed 文献 · Br J Haematol · 2023-08-10

这项回顾性研究纳入2014至2021年阿姆斯特丹2个中心接受非清髓预处理匹配无关供者造血干细胞移植的成人血液肿瘤患者(ATG组95例,PTCy组90例)。PTCy组急性GvHD II-IV级累积发生率显著低于ATG组(21%对48%,p<0.001),两组3年中重度慢性GvHD、复发率及总生存相似。作者结论认为PTCy方案急性GvHD发生率显著更低,PTCy是否改善总生存需更大前瞻性研究阐明。

要点

  • PTCy组急性GvHD II-IV级累积发生率为21%,低于ATG组的48%(p<0.001)。
  • 两组3年中重度慢性GvHD相似(p=0.69),复发率相当(ATG 31% vs PTCy 34%,p=0.94)。
  • ATG组非复发死亡率有升高趋势(17% vs 9%,p=0.069),总生存两组相似(p=0.12)。

核心结论

  • 在非清髓预处理的匹配无关供者造血干细胞移植中,PTCy方案较含ATG方案显著降低急性GvHD发生率。
  • PTCy是否较ATG改善总生存,需在更大规模的前瞻性研究中阐明。

研究设计与样本

  • 回顾性研究,纳入2014至2021年在阿姆斯特丹2个中心接受非清髓预处理匹配无关供者造血干细胞移植的成人血液系统恶性肿瘤患者。
  • ATG组95例,PTCy组90例,两组患者特征具有可比性。

主要发现

  • 急性GvHD II-IV级累积发生率ATG组48% vs PTCy组21%(p<0.001)。
  • 3年中重度慢性GvHD两组相似(p=0.69)。
  • 复发率ATG组31% vs PTCy组34%(p=0.94)。
  • 非复发死亡率ATG组17% vs PTCy组9%(p=0.069)。
  • 总生存两组相似(p=0.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性;作者在结论中指出PTCy是否改善总生存需在更大规模的前瞻性研究中阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GvHD) is a serious complication of allogeneic haematopoietic stem cell transplantation (HSCT). Both anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) are used as lymphocyte-depleting strategies, yet a systematic comparison of transplantation outcomes between these two methods in matched unrelated donors (MUD) transplantations with non-myeloablative conditioning (NMC) is lacking. Adult patients with haematological malignancies who had undergone MUD HSCT with NMC regimens between 2014 and 2021 at 2 centres in Amsterdam (ATG: n = 95, PTCy: n = 90), were included in this retrospective study. Patient characteristics were comparable between the groups. The cumulative incidence of acute GvHD grade II-IV was 48% in the ATG group compared to 21% in the PTCy group (p < 0.001). The 3-year moderate/severe chronic GvHD was similar in both groups (p = 0.69). While the relapse rate was comparable between the groups (ATG 31% vs. PTCy 34%, p = 0.94), non-relapse mortality tended to be higher in the ATG group (17% vs. 9%, p = 0.069). Overall survival was similar in both groups (p = 0.12). In conclusion, PTCy-based regimens resulted in a significantly lower rate of acute GvHD than ATG-containing regimens in MUD transplantations with NMC. Whether PTCy results in improved overall survival as compared to ATG needs to be elucidated in larger prospective studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Aydin M, de Leeuw DC, Rutten CE, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023. PMID: 37565363. doi:10.1111/bjh.19031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。